Generate Biomedicines, Inc. cash flow to debt ratio of -292.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Generate Biomedicines, Inc.'s free cash flow has decreased 68.43% from $-121.20M last year to $-204.13M, signaling decreasing performance

Generate Biomedicines, Inc.'s debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

Generate Biomedicines, Inc.'s debt has increased relative to shareholder equity from -0.18 last year to 0.14 today, signaling weakened financials

Generate Biomedicines, Inc. has a net cash position, so leverage is healthy.

Generate Biomedicines, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Generate Biomedicines, Inc.'s profit margin has decreased (11.93%) in the last year from -849.36% to -950.66%, signaling decreasing performance

Generate Biomedicines, Inc.'s short-term assets of $234.37M exceed its short-term liabilities of $82.20M

Generate Biomedicines, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Generate Biomedicines, Inc.'s return on equity of -26.51%, is lower than 15.00%, indicating bad performance

Generate Biomedicines, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Generate Biomedicines, Inc. has insufficient public price history to evaluate earnings stability.

Generate Biomedicines, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Generate Biomedicines, Inc. has negative free cash flow, indicating cash burn

Generate Biomedicines, Inc.'s yearly earnings has decreased 16.91% since last year from $-173.77M to $-203.15M, signaling decreasing performance

Generate Biomedicines, Inc. has insufficient data to evaluate this check.

ROIC -26.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Generate Biomedicines, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Generate Biomedicines, Inc. has insufficient public price history to evaluate revenue consistency.

Generate Biomedicines, Inc. has insufficient public price history to evaluate ROE consistency.

Generate Biomedicines, Inc. has insufficient data to evaluate this check.

Generate Biomedicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Generate Biomedicines, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Generate Biomedicines, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Generate Biomedicines, Inc. has insufficient data to evaluate this check.

Generate Biomedicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Generate Biomedicines, Inc. has a price-to-book ratio of 4.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Generate Biomedicines, Inc. has a price-to-sales ratio of 139.39x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue